celecoxib EG

Celecoxib EG is a generic formulation of the selective cyclooxygenase-2 (COX-2) inhibitor celecoxib, primarily indicated for the treatment of inflammatory conditions such as osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis. Developed and marketed by Eurogenerics (a subsidiary of STADA), this specific product has been utilized in clinical research at the University of Antwerp to investigate the 'inflammatory hypothesis' of major depressive disorder (MDD). The rationale for its use in MDD is that COX-2 inhibition reduces the production of pro-inflammatory prostaglandins, which are believed to contribute to the pathophysiology of depression. Researchers at the University of Antwerp have conducted Phase 2 clinical trials evaluating Celecoxib EG as an adjunctive therapy to standard antidepressants to improve clinical outcomes in patients with treatment-resistant or major depression.

Brand names

Celecoxib EGCelebrex

Other names

celecoxib